

## Treatment of Severe Heart Failure - AI

### **FineHeart awarded €2.5 million grant under the prestigious EIC Accelerator program, the first part of blended financing of up to €17.5 million for the development and clinical trials of the ICOMS FLOWMAKER®**

**Bordeaux, France, October 19, 2022** - FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced that it had been awarded a €2.5 million grant by the European Commission (EC) under the highly selective EIC Accelerator program. This grant has the potential to be followed by an equity investment of up to €15 million by the EIC Fund at the company's next series C funding round. It will support the industrialization and clinical trials of the ICOMS FLOWMAKER®.

*"The support of the European Union is of significant importance to FineHeart as we prepare for the First In Human implantation, scheduled for 2023. This recognition by the Experts of Europe illustrates our commitment to providing heart failure patients with a highly innovative, effective and sustainable treatment. It will have a very significant impact on our whole industrial and clinical development program. I am very proud to share this success with the whole FineHeart team, which has worked tirelessly to resolve all the scientific and technological hurdles of our device, with the international community of cardiologists who have been by our side since the beginning, and with our investors and partners who have supported us in reaching successfully this decisive milestone for the company."*  
declared **Arnaud Mascarell, CEO & co-founder of FineHeart.**

Learn more about the October 2022 candidates : <https://europa.eu/!7NrFkR>

#### **About the EIC Accelerator program**

The EIC Accelerator program is part of the European Innovation Council (EIC) project, which sits within the European Union's €95 billion Horizon Europe framework program for research and innovation. The EIC Accelerator offers start-ups and SMEs grants of up to €2.5 million combined with equity investments through the EIC Fund ranging from €0.5 to €15 million to help these companies develop and bring to market innovative products that can stimulate economic growth in Europe.

FineHeart is one of the 13 French companies to have been awarded funding during the latest round of the program which selected 75 European companies out of more than 1000 candidates.

**Advisors to FineHeart:** IXEO-Conseil – Laurence Riou – René Laversanne  
<https://www.ixeo-conseil.com/>

#### **About the ICOMS FLOWMAKER**

The ICOMS FLOWMAKER® is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the heart's natural contractions. It respects the natural blood flow and does not

require aortic bypass surgery. It is the first miniaturized device - barely 10 cm in size - that is adjustable to patients' needs, like a pacemaker, to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, which, on average lasts 90 minutes.

## About FineHeart

FineHeart is a medical device company that is developing its innovative ground-breaking product, ICOMS FLOWMAKER®, with the potential to treat 200,000 patients with severe heart failure each year. First-In-Human trials are expected in 2023. FineHeart will initially target the 50,000 most severe patients who are eligible for cardiac assistance. Initial estimates value this market segment to be worth over US\$5 billion.

Founded in 2010, FineHeart is based in Bordeaux employing close to 50 employees. It is led by a team of internationally renowned cardiac surgeons and electro-physiologists: Dr. Stéphane Garrigue, PhD, CSO co-inventor of ICOMS FLOWMAKER®; Dr. Philippe Ritter, MS, co-inventor of cardiac resynchronization (CRT); and Arnaud Mascarell, FineHeart's CEO. The company holds a portfolio of 72 patents in 18 families.

FineHeart is supported by a wide pool of public and private industrial and independent investors: Lauak Group, Doliam, Med-INNOV, FineHeart Founders' Holding representing domestic and international private investors, mainly from the cardiology sector, and the European investment fund Verve Ventures as well as historical shareholders Irdi, Aquiti, Galia, Broadview Ventures, and M Capital. FineHeart also benefits from the financial support of the European Union, Bpifrance, the New Aquitaine Region and the Centre Region.

<http://fineheart.fr/fr/accueil/>

---

## Contacts

### Europe

Media Relations  
Annie-Florence Loyer  
afloyer@newcap.fr  
+33 (6) 88 20 35

### FineHeart Communications

James Palmer  
j.palmer@orpheonfinance.com  
+33 (0) 7 60 92 77 72

---

28 Avenue Gustave Eiffel,  
Bâtiment C, 33600 Pessac - FR Tel:  
+33 5 64 31 18 40  
contact@fine-heart.com